Evidence map›Paper›PMID 36481066›Full record

ArticleBiological psychiatry2023

Anti-SARS-CoV-2 and Autoantibody Profiling of a COVID-19 Patient With Subacute Psychosis Who Remitted After Treatment With Intravenous Immunoglobulin.

Lindsay S McAlpine, Brooke Lifland, Joseph R Check, Gustavo A Angarita, Thomas T Ngo, Peixi Chen, Ravi Dandekar, Bonny D Alvarenga, Weston D Browne, Samuel J Pleasure and 4 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Biological psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lindsay S McAlpineDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut.
Brooke LiflandDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Joseph R CheckDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Gustavo A AngaritaDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
Thomas T NgoWeill Institute for Neurosciences, University of California, San Francisco, California; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California.
Peixi ChenWeill Institute for Neurosciences, University of California, San Francisco, California; Department of Neurology, University of California, San Francisco, California.
Ravi DandekarWeill Institute for Neurosciences, University of California, San Francisco, California; Department of Neurology, University of California, San Francisco, California.
Bonny D AlvarengaWeill Institute for Neurosciences, University of California, San Francisco, California; Department of Neurology, University of California, San Francisco, California.
Weston D BrowneWeill Institute for Neurosciences, University of California, San Francisco, California; Department of Neurology, University of California, San Francisco, California.
Samuel J PleasureWeill Institute for Neurosciences, University of California, San Francisco, California; Department of Neurology, University of California, San Francisco, California.
Michael R WilsonWeill Institute for Neurosciences, University of California, San Francisco, California; Department of Neurology, University of California, San Francisco, California.
Serena S SpudichDepartment of Neurology, Yale University School of Medicine, New Haven, Connecticut.
Shelli F FarhadianDepartment of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut.
Christopher M BartleyWeill Institute for Neurosciences, University of California, San Francisco, California; Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California. Electronic address: chris.bartley@nih.gov.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
CNS Viral Persistence and Neuropsychiatric Perturbations in HIV: Single cell and Molecular InterrogationR01MH125737 · NIMH · YALE UNIVERSITY · PI CYKTOR, JOSHUA CHARLES, SPUDICH, SERENA S · 2021 to 2025
$5.4M
PET IMAGING OF SYNAPTIC DENSITY COMBINED WITH NEUROIMMUNOLOGIC MEASURES TO REVEAL MECHANISMS OF HIV NEUROPATHOGENESIS DURING ARTR01MH125396 · NIMH · YALE UNIVERSITY · PI SPUDICH, SERENA S · 2020 to 2024
$4.7M
Autoimmune Encephalitis - Ataxia and Psychiatric Disease: Identifying and Characterizing Novel Antibody TargetsR01MH122471 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOSEPH L. DERISI, SAMUEL JEREMY PLEASURE · 2020 to 2026
$4.7M
Viral and immune-mediated CNS pathology during SARS-CoV-2 infectionR01AI157488 · NIAID · YALE UNIVERSITY · PI FARHADIAN, SHELLI, IWASAKI, AKIKO · 2020 to 2024
$4.7M
NeuroCovid Autoantibodies: Establishing a research pipelineR01NS118995 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PLEASURE, SAMUEL JEREMY · 2020 to 2024
$2.3M
Humoral Immune Mechanisms of Acute and Chronic Neurologic Sequelae of COVID-19R01NS125693 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PLEASURE, SAMUEL JEREMY, WILSON, MICHAEL R · 2022 to 2025
$2.3M
NMDA receptors and callosal circuitry: development and molecular mechanismsR01MH119435 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PLEASURE, SAMUEL JEREMY · 2020 to 2023
$1.6M
Understanding the cellular basis for persistent immune activation in the central nervous system during virologically suppressed HIVK23MH118999 · NIMH · YALE UNIVERSITY · PI FARHADIAN, SHELLI · 2018 to 2021
$770k
Illumina NovaSeq 6000 Sequencing SystemS10OD028511 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHOW, ERIC D · 2020 to 2020
$583k
Single cell RNAseq of CSF to Dissect CNS Cellular Perturbations in Long-term Treated HIVR21MH118109 · NIMH · YALE UNIVERSITY · PI SPUDICH, SERENA S · 2018 to 2019
$461k
NCATS NIH HHS UL1 TR001863NIAID NIH HHS R01 AI157488NIH HHS S10 OD028511NIMH NIH HHS K23 MH118999NIMH NIH HHS R01 MH119435NIMH NIH HHS R01 MH122471NIMH NIH HHS R01 MH125396NIMH NIH HHS R01 MH125737NIMH NIH HHS R21 MH118109NINDS NIH HHS R01 NS118995NINDS NIH HHS R01 NS125693
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Psychotic DisordersHumansImmunoglobulins, IntravenousSARS-CoV-2Immunoglobulins, Intravenous

Identifiers

PMID36481066
PMCPMC9722219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.